Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists

Elena Riboldi, Giada Frascaroli, Pietro Transidico, Walter Luini, Sergio Bernasconi, Francesca Mancini, Angelo Guglielmotti, Claudio Milanese, Mario Pinza, Silvano Sozzani, Alberto Mantovani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

1. The present study was aimed to investigate the effect of benzydamine, an anti-inflammatory drug devoid of activity on arachidonic acid metabolism, on monocyte chemotaxis and to define the possible biochemical correlates of activity. 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a. The effect was dose-dependent with IC 50's of 100, 50 and 45 μM for MCP-1/CCL2, fMLP and C5a, respectively. At the dose of 100 μM, the effect resulted in a 50 ± 10% inhibition of MCP-1/CCL2-induced chemotaxis and 53 ± 6 and 54 ± 5% inhibitions of chemotaxis in response of fMLP and C5a, respectively (n = 3). 3. Receptor expression as well as calcium fluxes in response to chemoattractants were not affected by benzydamine. 4. Benzydamine strongly inhibited chemoattractant-induced activation of the mitogen-activated protein kinase (MAPK) ERK1/2, and of its upstream activator kinase MEK1/2. ERK1/12 activation in response to chemoattractants was 89-98% inhibited by a 100 μM concentration of benzydamine with an IC 50 of 30 μM. 5. Under the same experimental conditions, pretreatment with 100 μM benzydamine caused a 75-89% inhibition of p38 activation (IC 50 25 μM). 6. These results indicate that the anti-inflammatory activity of benzydamine is exerted at multiple levels, including monocyte migration to chemotactic factors associated to a blockage of ERK and p38 MAPK pathways.

Original languageEnglish
Pages (from-to)377-383
Number of pages7
JournalBritish Journal of Pharmacology
Volume140
Issue number2
DOIs
Publication statusPublished - Sep 2003

Fingerprint

Benzydamine
Mitogen-Activated Protein Kinases
Monocytes
Chemotactic Factors
Chemotaxis
Anti-Inflammatory Agents
Cell Migration Inhibition
CC Chemokines
Chemokine CCL2
Mitogen-Activated Protein Kinase 1
p38 Mitogen-Activated Protein Kinases
Arachidonic Acid
Phosphotransferases
Calcium

Keywords

  • Benzydamine
  • Chemotaxis
  • ERK1/2
  • MAPK
  • Monocytes
  • p38 MAPK

ASJC Scopus subject areas

  • Pharmacology

Cite this

Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists. / Riboldi, Elena; Frascaroli, Giada; Transidico, Pietro; Luini, Walter; Bernasconi, Sergio; Mancini, Francesca; Guglielmotti, Angelo; Milanese, Claudio; Pinza, Mario; Sozzani, Silvano; Mantovani, Alberto.

In: British Journal of Pharmacology, Vol. 140, No. 2, 09.2003, p. 377-383.

Research output: Contribution to journalArticle

Riboldi, E, Frascaroli, G, Transidico, P, Luini, W, Bernasconi, S, Mancini, F, Guglielmotti, A, Milanese, C, Pinza, M, Sozzani, S & Mantovani, A 2003, 'Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists', British Journal of Pharmacology, vol. 140, no. 2, pp. 377-383. https://doi.org/10.1038/sj.bjp.0705428
Riboldi, Elena ; Frascaroli, Giada ; Transidico, Pietro ; Luini, Walter ; Bernasconi, Sergio ; Mancini, Francesca ; Guglielmotti, Angelo ; Milanese, Claudio ; Pinza, Mario ; Sozzani, Silvano ; Mantovani, Alberto. / Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists. In: British Journal of Pharmacology. 2003 ; Vol. 140, No. 2. pp. 377-383.
@article{8dd5acb902a84462abe6cf3252f7506c,
title = "Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists",
abstract = "1. The present study was aimed to investigate the effect of benzydamine, an anti-inflammatory drug devoid of activity on arachidonic acid metabolism, on monocyte chemotaxis and to define the possible biochemical correlates of activity. 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a. The effect was dose-dependent with IC 50's of 100, 50 and 45 μM for MCP-1/CCL2, fMLP and C5a, respectively. At the dose of 100 μM, the effect resulted in a 50 ± 10{\%} inhibition of MCP-1/CCL2-induced chemotaxis and 53 ± 6 and 54 ± 5{\%} inhibitions of chemotaxis in response of fMLP and C5a, respectively (n = 3). 3. Receptor expression as well as calcium fluxes in response to chemoattractants were not affected by benzydamine. 4. Benzydamine strongly inhibited chemoattractant-induced activation of the mitogen-activated protein kinase (MAPK) ERK1/2, and of its upstream activator kinase MEK1/2. ERK1/12 activation in response to chemoattractants was 89-98{\%} inhibited by a 100 μM concentration of benzydamine with an IC 50 of 30 μM. 5. Under the same experimental conditions, pretreatment with 100 μM benzydamine caused a 75-89{\%} inhibition of p38 activation (IC 50 25 μM). 6. These results indicate that the anti-inflammatory activity of benzydamine is exerted at multiple levels, including monocyte migration to chemotactic factors associated to a blockage of ERK and p38 MAPK pathways.",
keywords = "Benzydamine, Chemotaxis, ERK1/2, MAPK, Monocytes, p38 MAPK",
author = "Elena Riboldi and Giada Frascaroli and Pietro Transidico and Walter Luini and Sergio Bernasconi and Francesca Mancini and Angelo Guglielmotti and Claudio Milanese and Mario Pinza and Silvano Sozzani and Alberto Mantovani",
year = "2003",
month = "9",
doi = "10.1038/sj.bjp.0705428",
language = "English",
volume = "140",
pages = "377--383",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists

AU - Riboldi, Elena

AU - Frascaroli, Giada

AU - Transidico, Pietro

AU - Luini, Walter

AU - Bernasconi, Sergio

AU - Mancini, Francesca

AU - Guglielmotti, Angelo

AU - Milanese, Claudio

AU - Pinza, Mario

AU - Sozzani, Silvano

AU - Mantovani, Alberto

PY - 2003/9

Y1 - 2003/9

N2 - 1. The present study was aimed to investigate the effect of benzydamine, an anti-inflammatory drug devoid of activity on arachidonic acid metabolism, on monocyte chemotaxis and to define the possible biochemical correlates of activity. 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a. The effect was dose-dependent with IC 50's of 100, 50 and 45 μM for MCP-1/CCL2, fMLP and C5a, respectively. At the dose of 100 μM, the effect resulted in a 50 ± 10% inhibition of MCP-1/CCL2-induced chemotaxis and 53 ± 6 and 54 ± 5% inhibitions of chemotaxis in response of fMLP and C5a, respectively (n = 3). 3. Receptor expression as well as calcium fluxes in response to chemoattractants were not affected by benzydamine. 4. Benzydamine strongly inhibited chemoattractant-induced activation of the mitogen-activated protein kinase (MAPK) ERK1/2, and of its upstream activator kinase MEK1/2. ERK1/12 activation in response to chemoattractants was 89-98% inhibited by a 100 μM concentration of benzydamine with an IC 50 of 30 μM. 5. Under the same experimental conditions, pretreatment with 100 μM benzydamine caused a 75-89% inhibition of p38 activation (IC 50 25 μM). 6. These results indicate that the anti-inflammatory activity of benzydamine is exerted at multiple levels, including monocyte migration to chemotactic factors associated to a blockage of ERK and p38 MAPK pathways.

AB - 1. The present study was aimed to investigate the effect of benzydamine, an anti-inflammatory drug devoid of activity on arachidonic acid metabolism, on monocyte chemotaxis and to define the possible biochemical correlates of activity. 2. Benzydamine inhibited monocyte chemotaxis in response to three classes of chemoattractants: the prototypic CC-chemokine CCL2 (MCP-1), the microbial product fMLP and the complement cascade component C5a. The effect was dose-dependent with IC 50's of 100, 50 and 45 μM for MCP-1/CCL2, fMLP and C5a, respectively. At the dose of 100 μM, the effect resulted in a 50 ± 10% inhibition of MCP-1/CCL2-induced chemotaxis and 53 ± 6 and 54 ± 5% inhibitions of chemotaxis in response of fMLP and C5a, respectively (n = 3). 3. Receptor expression as well as calcium fluxes in response to chemoattractants were not affected by benzydamine. 4. Benzydamine strongly inhibited chemoattractant-induced activation of the mitogen-activated protein kinase (MAPK) ERK1/2, and of its upstream activator kinase MEK1/2. ERK1/12 activation in response to chemoattractants was 89-98% inhibited by a 100 μM concentration of benzydamine with an IC 50 of 30 μM. 5. Under the same experimental conditions, pretreatment with 100 μM benzydamine caused a 75-89% inhibition of p38 activation (IC 50 25 μM). 6. These results indicate that the anti-inflammatory activity of benzydamine is exerted at multiple levels, including monocyte migration to chemotactic factors associated to a blockage of ERK and p38 MAPK pathways.

KW - Benzydamine

KW - Chemotaxis

KW - ERK1/2

KW - MAPK

KW - Monocytes

KW - p38 MAPK

UR - http://www.scopus.com/inward/record.url?scp=10744230952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230952&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705428

DO - 10.1038/sj.bjp.0705428

M3 - Article

C2 - 12970098

AN - SCOPUS:10744230952

VL - 140

SP - 377

EP - 383

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -